Clinical Trial Update: Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 1]

View source ↗

Summary

This Phase 1 trial investigates fludarabine and cyclophosphamide with or without rituximab as a lymphodepletion regimen before CD19 CAR-T cell therapy in relaps…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CD19 Chimeric Antigen Receptor T Cells (CD19 CAR T-cell therapy)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Rituximab (rituximab)

Snippet

Sponsor: Mehrdad Abedi, MD | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Status: RECRUITING